Generic formulations of imatinib for treatment of Philadelphia chromosome–positive leukemia in pediatric patients

Meinolf Suttorp, Markus Metzler, Frederic Millot, Hiroyuki Shimada, Deepak Bansal, Adalet Meral Günes, Krzysztof Kalwak, Petr Sedlacek, Andre Baruchel, Andrea Biondi, Nobuko Hijiya, Kirk R. Schultz, Martin Schrappe

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Since the patent for imatinib has expired, the role of generic imatinib (GI) in the management of Philadelphia chromosome–positive (Ph+) leukemia in pediatric patients has had ongoing discussion. Some studies in adults demonstrated that equivalent doses of GI and branded imatinib (BI) result in comparable plasma concentrations and clinical efficacy. However, other studies found that GI users are more likely to stop imatinib, with intolerance and decreased persistence as the main causes. Economic factors also heavily influence GI selection. This article aims to review the present knowledge to support further discussion on the role of GI in the management of pediatric Ph+ leukemia.

Original languageEnglish
JournalPediatric Blood and Cancer
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Keywords

  • generic medication
  • imatinib inhibitor
  • pediatric
  • Ph+ leukemia
  • tyrosine kinase

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Generic formulations of imatinib for treatment of Philadelphia chromosome–positive leukemia in pediatric patients'. Together they form a unique fingerprint.

  • Cite this

    Suttorp, M., Metzler, M., Millot, F., Shimada, H., Bansal, D., Günes, A. M., Kalwak, K., Sedlacek, P., Baruchel, A., Biondi, A., Hijiya, N., Schultz, K. R., & Schrappe, M. (Accepted/In press). Generic formulations of imatinib for treatment of Philadelphia chromosome–positive leukemia in pediatric patients. Pediatric Blood and Cancer. https://doi.org/10.1002/pbc.27431